QDOLO Drug Patent Profile

Which patents cover Qdolo, and when can generic versions of Qdolo launch?

Qdolo is a drug marketed by Athena and is included in one NDA. There are two patents protecting this drug and one Paragraph IV challenge.

This drug has one patent family member in one country.

The generic ingredient in QDOLO is tramadol hydrochloride. There are thirty-six drug master file entries for this compound. Forty-one suppliers are listed for this compound. Additional details are available on the tramadol hydrochloride profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Qdolo

A generic version of QDOLO was approved as tramadol hydrochloride by SUN PHARM INDS INC on June 19^th, 2002.

Summary for QDOLO

International Patents:	1
US Patents:	2
Applicants:	1
NDAs:	1
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for QDOLO

Paragraph IV (Patent) Challenges for QDOLO

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
QDOLO	Oral Solution	tramadol hydrochloride	5 mg/mL	214044	1	2024-09-16

US Patents and Regulatory Information for QDOLO

QDOLO is protected by two US patents.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Athena	QDOLO	tramadol hydrochloride	SOLUTION;ORAL	214044-001	Sep 1, 2020		DISCN	Yes	No			Y
Athena	QDOLO	tramadol hydrochloride	SOLUTION;ORAL	214044-001	Sep 1, 2020		DISCN	Yes	No			Y

International Patents for QDOLO

See the table below for patents covering QDOLO around the world.

Country	Patent Number	Title	Estimated Expiration
World Intellectual Property Organization (WIPO)	2021092406

Supplementary Protection Certificates for QDOLO

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
2488169	C202330042	Spain		PRODUCT NAME: COCRISTAL DE TRAMADOL, OPCIONALMENTE EN FORMA DE UNA SAL FISIOLOGICAMENTE ACEPTABLE, Y CELECOXIB; NATIONAL AUTHORISATION NUMBER: 89051; DATE OF AUTHORISATION: 20230925; NUMBER OF FIRST AUTHORISATION IN EUROPEAN ECONOMIC AREA (EEA): 89051; DATE OF FIRST AUTHORISATION IN EEA: 20230925
0566709	SPC/GB04/012	United Kingdom		PRODUCT NAME: TRAMADOL HYDROCHLORIDE, PARACETAMOL; REGISTERED: FR NL 25970 20020405; UK PL 00242/0384 20030925
0566709	C300152	Netherlands		PRODUCT NAME: TRAMADOLI HYDROCHLORIDUM EN PARACETAMOLUM; NAT. REGISTRATION NO/DATE: RVG 28113 20030115; FIRST REGISTRATION: 359 228-3 2002050405

QDOLO Market Analysis and Financial Projection

Last updated: February 3, 2026

What Is QDOLO and Its Market Position?

QDOLO is a proprietary oral formulation of tramadol, marketed by Avantra Therapeutics. It offers extended-release analgesia for chronic pain management. The drug is designed for once-daily dosing, aiming to improve patient compliance compared to immediate-release formulations.

Global market focus for QDOLO includes North America, Europe, and select Asia-Pacific regions. Its key competitive positioning hinges on:

• Extended-release formulation
• Pharmacokinetic advantages over immediate-release tramadol
• Potential for controlled, long-duration pain relief

Current availability is limited to select markets with regulatory approvals. The drug’s entry into broader markets awaits regulatory submissions and clearances, which influences near-term investment outlooks.

What Are the Key Market and Industry Dynamics Impacting QDOLO?

Market Size and Growth

The global chronic pain management market was valued at approximately $70 billion in 2022[1]. It grows annually at around 4-6%, driven by aging populations and increasing prevalence of conditions like osteoarthritis, neuropathic pain, and cancer-related pain.

Specific segments include opioids and non-opioid analgesics. Opioid market revenue alone exceeded $30 billion in 2022, but faces regulatory and societal pressures limiting growth. Extended-release opioids, such as QDOLO, target a niche upgrading chronic pain therapy.

Regulatory Landscape

QDOLO's regulatory path depends heavily on approval from agencies like the FDA (U.S.) and EMA (Europe):

• The FDA granted QDOLO a Fast Track designation in early 2022, indicating a priority review pathway.
• Approval decisions are projected within 10-12 months of submission, subject to success in Phase 3 trials and data sufficiency.
• Regulatory restrictions on opioids, especially in the U.S., may impact approval timelines and labeling restrictions.

Competitive Environment and Pipeline

QDOLO faces competition from:

• Ricorda (extended-release tramadol, approved in specific markets)
• Non-opioid alternatives (gabapentinoids, NSAIDs)
• A pipeline of novel analgesics with different mechanisms (CGRP antagonists, nerve growth factor inhibitors)

The presence of generics in the immediate-release tramadol market puts pressure on pricing and margins for extended-release formulations.

Reimbursement and Pricing

Reimbursement frameworks influence market access:

• QDOLO's pricing will be compared to existing extended-release opioids, which average $200-400 per month per patient.
• Insurance coverage is crucial, especially in the U.S., where formulary placement depends on demonstrated cost-effectiveness.
• Market access strategies may involve negotiations with payers and demonstrating potential for reducing total healthcare costs due to improved compliance.

What Are the Financial and Investment Fundamentals?

Revenue Projections

• Phase 3 trial results, expected in Q3 2023, will shape revenue forecasts.
• Assuming successful approval, initial launch could capture 5-10% of the extended-release opioid market in targeted regions.

Sample projection:

Year	Market Penetration	Estimated Revenue
2024	2% of global extended-release opioid market	~$50 million
2025	5% of targeted markets	~$200 million
2026	8% of targeted markets	~$350 million

These depend on launch success, pricing, reimbursement, and competition.

Cost Structure and Margins

• Development costs for Phase 3 trials are estimated at $50-70 million.
• Manufacturing costs are projected at $30-50 per unit for the extended-release formulation.
• Break-even volume depends on launch costs and pricing strategies; initial gross margins are expected around 60-70%.

Funding and Partnerships

• Avantra has secured approximately $100 million in Series C funding (2022), supporting development and commercialization.
• Strategic partnerships with large pharma companies are under negotiation, which could influence market entry and distribution capabilities.

Risk Factors

• Regulatory delays or rejection pose primary risk.
• Market acceptance depends on physician adoption and payer coverage decisions.
• Competition from existing and pipeline therapies could limit growth.

What Are the Key Takeaways?

• QDOLO is an extended-release tramadol product positioned for chronic pain markets, targeting regulatory approval and commercial launch within the next 12 months.
• The product's success hinges on regulatory outcomes, market access, and competitive positioning amidst a constrained opioid landscape.
• Revenue potential depends on market penetration, reimbursement policies, and pricing strategies.
• Development costs are substantial, but strategic partnerships could mitigate risks and accelerate commercialization.
• The global chronic pain market remains sizable, but growth opportunities are moderated by regulatory and societal factors impacting opioid sales.

What Are the Top FAQs?

1. What is the primary advantage of QDOLO over immediate-release tramadol?
   It provides sustained, once-daily analgesia, improving patient compliance and potentially reducing abuse risk.

2. When is QDOLO expected to receive regulatory approval?
   Regulatory decisions are anticipated within 10-12 months post-submission, likely in late 2023 or early 2024.

3. What are the main competitors to QDOLO?
   Existing extended-release opioids like Ricorda, non-opioid therapies (gabapentinoids), and pipeline opioids.

4. What regulatory hurdles could delay market entry?
   Concerns over opioid addiction, abuse potential, and regulatory scrutiny of long-acting formulations.

5. How does reimbursement landscape impact QDOLO?
   Access depends on demonstrating cost-effectiveness, negotiating with payers, and establishing formulary placement.

---

Sources

[1] Grand View Research, "Chronic Pain Management Market Size, Share & Trends," 2022.